By: Dawn Dorsey
A type of drug that blocks the binding of cancer-promoting proteins may be suitable for treatment-resistant non-small cell lung cancer (NSCLC), especially if a specific growth factor is activated, according to a case study published today in the Clinical Therapeutics section of The New England Journal of Medicine.
The article, written by a team of researchers while they were fellows at The University of Texas MD Anderson Cancer Center, outlines the available data about use of these drugs, known as oral tyrosine kinase inhibitors, in the treatment of lung cancer patients.
